by 
Urinary tract infections (UTIs) refer to infections that affect any part of the urinary system including the kidneys, ureters, bladder, and urethra. UTIs are commonly caused by bacterial infection and can be classified into complicated and uncomplicated UTIs based on several factors such as the site of infection, underlying conditions, and mode of acquisition. UTIs are among the most commonly reported healthcare-associated infections. In particular, hospital-acquired UTIs pose a significant burden on healthcare systems owing to increased medication use, prolonged hospital stay, and high mortality rates. With the rising geriatric population worldwide and increasing incidence of hospital-acquired UTIs, the demand for effective UTI therapies is expected to surge in the coming years.
The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The increasing incidence of hospital-acquired UTIs is expected to be a major driver for the Urinary Tract Infection Therapeutic Market over the forecast period. According to the Centers for Disease Control and Prevention (CDC), UTIs are the most common HAIs accounting for over 30% of total HAIs reported each year in the United States. Risk factors associated with hospitalizations such as invasive devices, immunosuppression, and prolonged antibiotic use make patients more vulnerable to UTIs during medical care. With the growing geriatric population and rising number of hospital visits each year globally, the prevalence of hospital-acquired UTIs is estimated to surge significantly.
Another driver for the market growth is the introduction of innovative therapies to treat drug-resistant infections. The rising antibiotic resistance is a pressing challenge faced in the treatment of various diseases including UTIs. To counter this issue, key players are engaged in developing novel drug delivery mechanisms and combination therapies with improved efficacy. For instance, in March 2022, MicuRx Pharmaceuticals announced positive results from a Phase I trial of MRX-4, an inhaled dispersion of ciprofloxacin to treat ventilator-associated bacterial pneumonia and hospital-acquired pneumonia, including multidrug-resistant strains. Such innovations are expected to augment the demand for advanced UTI treatments during the forecast period.
Segment Analysis
The global urinary tract infection therapeutic market is dominated by the cephalosporins sub segment, which holds approximately 30% share of the market owing to its wide acceptance and effectiveness. The cephalosporins like cefdinir and cefuroxime axetil are predominantly prescribed for the treatment of uncomplicated UTI. Fluoroquinolones are the second largest sub segment with a share of around 25% as they are effective against both gram positive and gram negative bacteria.
PEST Analysis
Political: Government initiatives to spread awareness regarding personal hygiene and sanitation has helped reduce the incidence of UTI to some extent. Various agencies are working on guidelines to curb overuse and misuse of antibiotics.
Economic: Rising healthcare expenditure coupled with growing geriatric population which is more prone to UTI, especially in developed economies is supporting market growth. However, price controls and generic competition are restraining pricing flexibility of players.
Social: Better access to healthcare services and improving lifestyles has enhanced diagnosis and treatment seeking rate for UTI. However, social stigma still exists regarding genitourinary infections especially in developing regions.
Technological: Advanced diagnostic tests help early and accurate diagnosis of complicated UTI. New drug delivery systems and combination therapies are being researched to enhance efficacy and ensure patient adherence.
Key Takeaways
The global urinary tract infection therapeutic market is expected to witness high growth over the forecast period. The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030.
North America currently dominates the market owing to higher diagnosis rates and healthcare spending. In North America, the United States holds the major market share primarily due to well established healthcare infrastructure and favorable reimbursement policies promoting access to medicines. The Asia Pacific region is witnessing fastest growth in the urinary tract infection therapeutic market driven by rising public healthcare investments, growing medical tourism, and increasing awareness about UTI diagnosis and treatment. Countries like India, China and Japan are main revenue generators in the region supported by their large population base and improving access to products and services.
Key players related content:
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC. Pfizer leads with its broad antibiotic portfolio including generic drugs like cephalexin and branded ones like ciprofloxacin which are frequently prescribed by physicians for UTI treatment.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
